Historical performance in the Biotechnology category.
Source: Acquire.fyi, Jan 1, 2025 - Jul 13, 2026.
Largest mergers and acquisitions by disclosed deal value.
| Acquirer | Target | Type | Value | Headline |
|---|---|---|---|---|
| Abbott Laboratories | Exact Sciences | Acquisition | $21.3B | Abbott Laboratories acquires Exact Sciences in $21,267.5M deal |
| Gilead Sciences | Arcellx | Acquisition | $7.6B | Gilead Sciences acquires Arcellx in $7,589.0M deal |
| Novartis | Myricx Bio | Acquisition | $1.5B | Novartis Bets $1.5 Billion on Myricx ADC Payload Platform |
| Zoetis Inc. | Neogen Corporation | Acquisition | $160M | Zoetis Inc. to acquire Neogen Corporation in $160.0M cash deal |
| Fertio | Cascade Cryobank | Acquisition | Undisclosed | Fertio acquires Cascade Cryobank |
| insitro | CombinAbleAI | Acquisition | Undisclosed | insitro to acquire CombinAbleAI |
| Apimeds Pharmaceuticals US, Inc. | MindWave Innovations Inc | Merger | Undisclosed | Apimeds Pharmaceuticals US, Inc. to merge with MindWave Innovations Inc |
| Colossal Biosciences | Viagen Pets and Equine | Acquisition | Undisclosed | Colossal Biosciences acquires Viagen Pets and Equine |
| Edwards Lifesciences Corporation | JenaValve Technology | Acquisition | Undisclosed | Edwards Lifesciences Corporation to acquire JenaValve Technology |
| Astro Pak LLC | Clean Sciences, LLC | Acquisition | Undisclosed | Astro Pak LLC acquires Clean Sciences, LLC |
Page 1 of latest articles and deal coverage.
The deal gives Novartis a differentiated antibody drug conjugate engine as large pharma races to secure better-tolerated oncology assets before clinical validation drives prices higher.